Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(16 sites)
United States
UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California UCLA, Santa Monica, California Moffitt Cancer Center, Tampa, Florida Johns Hopkins University, Baltimore, Maryland Dana Farber Cancer Institute, Boston, Massachusetts Perlmutter Cancer Center at NYU Langone Health, New York, New York Memorial Sloan-Kettering Cancer Center, New York, New York Columbia University, New York, New York Christ Hospital Cancer Center, Cincinnati, Ohio Sarah Cannon Research Institute, Nashville, Tennessee University of Texas at Austin, Austin, Texas Mary Crowley Cancer Research, Dallas, Texas The University of Texas MD Anderson Cancer Center, Houston, Texas Next Oncology, San Antonio, Texas Huntsman Cancer Institute, Salt Lake City, Utah Next Oncology Virginia, Fairfax, Virginia